பென்ட்லி பல்கலைக்கழகம் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பென்ட்லி பல்கலைக்கழகம் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பென்ட்லி பல்கலைக்கழகம் மையம் Today - Breaking & Trending Today

COVID-19 vaccine development built on >$17 billion in NIH funding for vaccine technologies


Credit: © Center for Integration of Science and Industry at Bentley University
The unprecedented development of COVID-19 vaccines less than a year after discovery of this virus was enabled by more than $17 billion of research on vaccine technologies funded by the NIH prior to the pandemic, according to new research from Bentley University sCenter for Integration of Science and Industry. The article, titled NIH funding for vaccine readiness before the COVID-19 pandemic, demonstrates the critical role this broad foundation of government-funded research plays in ensuring vaccine readiness.
The report, published today in the journal
Vaccine, examined the maturation of research and NIH funding for ten technologies that were applied in candidate COVID-19 vaccines as of July 2020. The maturation of these technologies was described in 51,530 published research papers from 2000-2019, of which 8,420 (16%) acknowledge NIH funding totaling $17.2 billion. Some of these technolo ....

United States , Helen Henrichs , Ekaterina Galkina Cleary , Fredd Ledley , Matthew Jackson , Anthony Kiszewski , Fred Ledley , National Biomedical Research Foundation , Bentley University , Bentley University Center , Edward Jenner Society , Japanese Society For Vaccinology , Associate Professor , Applied Science , National Biomedical Research , Japanese Society , ஒன்றுபட்டது மாநிலங்களில் , ஹெலன் ஹென்ரிச் , மேத்யூ ஜாக்சன் , தேசிய உயிர் மருத்துவ ஆராய்ச்சி அடித்தளம் , பென்ட்லி பல்கலைக்கழகம் , பென்ட்லி பல்கலைக்கழகம் மையம் , எட்வர்ட் ஜென்னர் சமூகம் , ஜப்பானிய சமூகம் க்கு தடுப்பூசி , இணை ப்ரொஃபெஸர் , பயன்படுத்தப்பட்டது அறிவியல் ,

Investment risk & return from emerging public biotech companies comparable to non-biotech


 E-Mail
IMAGE: Shareholder value at the end of 2016 compared to IPO for biotech companies and paired controls completing IPOs 1997-2016. Net growth in shareholder value, and the fraction of companies generating.
view more 
Credit: Center for Integration of Science and Industry, Bentley University
Investing in biotech companies may not entail higher risk than investing in other sectors, according to a new report from Bentley University s Center for Integration of Science and Industry. A large scale study of biotechnology companies that completed Initial Public Offerings (IPOs) from 1997-2016 demonstrates that these companies produced more than $100 billion in shareholder value and almost $100 billion in new value creation despite a failure rate greater than 50%. The study compared the financial performance and economic value created by these biotech companies to non-biotechnology controls that had similarly timed IPOs. ....

United States , Ekaterina Galkina Cleary , Jeremy Holden , Liam Fitzgerald , Lauram Mcnamee , Fred Ledley , National Biomedical Research Foundation , Bentley University , Bentley University Center , Initial Public Offerings , Skyler De Boer , National Biomedical Research , ஒன்றுபட்டது மாநிலங்களில் , ஜெர்மி பிடி , லியாம் ஃபிட்ஸ்‌ஜெரல்ட் , தேசிய உயிர் மருத்துவ ஆராய்ச்சி அடித்தளம் , பென்ட்லி பல்கலைக்கழகம் , பென்ட்லி பல்கலைக்கழகம் மையம் , ஆரம்ப பொது பிரசாதம் , ஸ்கைலர் டி போயர் , தேசிய உயிர் மருத்துவ ஆராய்ச்சி ,